Publications

1. Sung H, Filho AM, Laversanne M, Ferlay J, Siegel RL, Soerjomataram I, et al. (2026). Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin. https://doi.org/10.3322/caac.70090
2. Morgan E, Bardot A, Langselius O, Rutherford MJ, Elkader HA, Bennett D, et al. (2026). International disruptions to cancer diagnosis and stage at presentation during the COVID-19 pandemic in 2020: an International Cancer Benchmarking Partnership (ICBP) population-based study. Lancet Oncol. 27(6):738–50. https://doi.org/10.1016/S1470-2045(26)00089-6 PMID:42225103
3. Barchuk A, Vignat J, Wiggins C, Bray F, Znaor A (2026). Global variations in kidney cancer incidence based on recorded cancer registry data. J Natl Cancer Inst. djag140. https://doi.org/10.1093/jnci/djag140 PMID:42097291
4. Ngo P, Shah R, Vignat J, Collins L, Cunnama L, Hwang I, et al. (2026). The direct costs of cancer care: a review of recent trends and variations in 39 countries. J Natl Cancer Inst Monogr. 2026(72):3–14. https://doi.org/10.1093/jncimonographs/lgag005 PMID:42008724
5. Fink H, Soerjomataram I, Bardot A, Brennan A, Woods RR, Gonsalves L, et al. (2026). International comparisons of survival after recurrent metastatic breast cancer in four countries: a population-based study. Breast. 87:104778. https://doi.org/10.1016/j.breast.2026.104778 PMID:41955991
6. Vaccarella S, Li M, Auvinen A, Dal Maso L (2026). Population impact of PSA screening: evidence beyond clinical trials. Eur J Cancer. 238:116615. https://doi.org/10.1016/j.ejca.2026.116615 PMID:41780182
7. Langselius O, Rumgay H, Vignat J, Charvat H, Rutherford MJ, Mafra A, et al. (2026). Avoidable deaths through the primary prevention, early detection, and curative treatment of cancer worldwide: a population-based study. Lancet Glob Health. 14(3):e356–66. https://doi.org/10.1016/S2214-109X(25)00494-2 PMID:41713439
8. Fink H, Langselius O, Vignat J, Rumgay H, Rehm J, Martinez RX, et al. (2026). Global and regional cancer burden attributable to modifiable risk factors to inform prevention. Nat Med. 32(4):1306–15. https://doi.org/10.1038/s41591-026-04219-7 PMID:41634393
9. Znaor A, Rous B, Levy GG, Watanabe R, Jakob R, Krpelanova E, et al. (2026). The International Classification of Diseases for Oncology, 4th Edition (ICD-O-4): an overview. Cancer Epidemiol. 101:102989. https://doi.org/10.1016/j.canep.2026.102989 PMID:41576584
10. Filho AM, Briganti A, Jemal A, Bray F (2026). Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 89(5):426–36. https://doi.org/10.1016/j.eururo.2025.12.011 PMID:41421927
11. Daltveit DS, Morgan E, Bardot A, Steliarova-Foucher E, Damie A, Hagenimana M, et al. (2025). Childhood cancer survival in Africa, Asia, Latin America and the Caribbean, during 2008–2017 (SURVCAN-3): a population-based benchmarking study of 16 821 children. J Natl Cancer Inst. djaf321. https://doi.org/10.1093/jnci/djaf321 PMID:41391483
12. Rumgay H, Colombet M, Ramos da Cunha A, Filho AM, Warnakulasuriya S, Conway DI, et al. (2026). Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022. CA Cancer J Clin. 76(1):caac.70048. https://doi.org/10.3322/caac.70048 PMID:41335400
13. Li M, Dal Maso L, Pizzato M, Rumgay H, Vaccarella S (2026). Thyroid cancer in adolescents and young adults: a population-based study in 185 countries worldwide. Lancet Diabetes Endocrinol. 14(2):112–22. https://doi.org/10.1016/S2213-8587(25)00289-X PMID:41274302 [Erratum in: Lancet Diabetes Endocrinol. 2026 Jan;14(1):e1. https://doi.org/10.1016/S2213-8587(25)00359-6 PMID:41285133]
14. Kong YC, Niyigaba J, Tran PB, Vignat J, Bray F, Gauvreau CL, et al. (2025). Global paid and unpaid productivity losses due to cancer-related mortality. J Natl Cancer Inst. 117(12):2612–20. https://doi.org/10.1093/jnci/djaf193 PMID:40987468
15. Pizzato M, McCormack V, Dossus L, Al-Alem U, Delpierre C, Lamy S, et al. (2025). Education level and risk of breast cancer by tumor subtype in the EPIC cohort. Int J Cancer. 157(4):672–86. https://doi.org/10.1002/ijc.35413 PMID:40170258
16. Znaor A, Fouad H, Zahwe M, Eser S, Fadhil I, Soerjomataram I, et al. (2025). Cancer surveillance in the Eastern Mediterranean region: a 10-year International Agency for Research on Cancer–WHO Regional Office for the Eastern Mediterranean collaboration. Lancet Oncol. 26(3):e131–9. https://doi.org/10.1016/S1470-2045(24)00624-7 PMID:40049204
17. Dee EC, Laversanne M, Bhoo-Pathy N, Ho FDV, Feliciano EJG, Eala MAB, et al. (2025). Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis. Lancet Oncol. 26(4):516–28. https://doi.org/10.1016/S1470-2045(25)00017-8 PMID:40024257
18. Luo G, Zhang Y, Rumgay H, Morgan E, Langselius O, Vignat J, et al. (2025). Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study. Lancet Respir Med. 13(4):348–63. https://doi.org/10.1016/S2213-2600(24)00428-4 PMID:39914442
19. Shah R, Hanna NM, Loo CE, David M, Mafra A, Fink H, et al. (2025). The global impact of the COVID-19 pandemic on delays and disruptions in cancer care services: a systematic review and meta-analysis. Nat Cancer. 6(1):194–204. https://doi.org/10.1038/s43018-024-00880-4 PMID:39747650
20. Filho AM, Laversanne M, Ferlay J, Colombet M, Piñeros M, Znaor A, et al. (2025). The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer. 156(7):1336–46. https://doi.org/10.1002/ijc.35278 PMID:39688499